Ipralin Special Precautions

Ipratropium bromide containing inhaler should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction.
Salbutamol sulphate containing inhaler should be used with caution in patients with convulsive disorders, hyperthyroidism or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines.
Beta-adrenergic agents may also produce significant hypokalemia in some patients (possibly through intracellular shunting) which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Combination of ipratropium and salbutamol inhaler has not been studied in patients with hepatic or renal insufficiency. it should be used with caution in those patient populations.
Use in pregnancy: Pregnancy Category C: There are no adequate and well-controlled studies of ipratropium bromide or salbutamol sulphate in pregnant women. Ipralin HFA inhaler should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in lactation: It is not known whether the components of Ipralin HFA inhaler are excreted in human milk. Ipralin HFA inhaler should not be used by breastfeeding mothers, unless the expected benefit is thought to outweigh the risks.
Use in children: Safety and effectiveness in the pediatric population have not been established.